David A. Collet, Julia Canestraro, Ghassan K. Abou-Alfa, David H. Abramson, Eli L. Diamond, J. Francis
{"title":"MEK 抑制剂相关性眼压升高","authors":"David A. Collet, Julia Canestraro, Ghassan K. Abou-Alfa, David H. Abramson, Eli L. Diamond, J. Francis","doi":"10.1159/000535427","DOIUrl":null,"url":null,"abstract":"Mitogen-activated protein kinase kinase (MEK) inhibitors are targeted anti-cancer agents that are prescribed to treat a broad range of cancers. Despite their strong efficacy profile, MEK inhibitors have been associated with ocular toxicities, most notably, self-limited serous detachments of the neurosensory retina. In this report, we outline three cases of a rarely documented toxicity, MEK inhibitor-associated ocular hypertension.","PeriodicalId":506981,"journal":{"name":"Ocular Oncology and Pathology","volume":"26 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"MEK Inhibitor-Associated Ocular Hypertension\",\"authors\":\"David A. Collet, Julia Canestraro, Ghassan K. Abou-Alfa, David H. Abramson, Eli L. Diamond, J. Francis\",\"doi\":\"10.1159/000535427\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Mitogen-activated protein kinase kinase (MEK) inhibitors are targeted anti-cancer agents that are prescribed to treat a broad range of cancers. Despite their strong efficacy profile, MEK inhibitors have been associated with ocular toxicities, most notably, self-limited serous detachments of the neurosensory retina. In this report, we outline three cases of a rarely documented toxicity, MEK inhibitor-associated ocular hypertension.\",\"PeriodicalId\":506981,\"journal\":{\"name\":\"Ocular Oncology and Pathology\",\"volume\":\"26 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ocular Oncology and Pathology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000535427\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ocular Oncology and Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000535427","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Mitogen-activated protein kinase kinase (MEK) inhibitors are targeted anti-cancer agents that are prescribed to treat a broad range of cancers. Despite their strong efficacy profile, MEK inhibitors have been associated with ocular toxicities, most notably, self-limited serous detachments of the neurosensory retina. In this report, we outline three cases of a rarely documented toxicity, MEK inhibitor-associated ocular hypertension.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
